IP Library Granted Patent US 7,799,826
Granted Patent B2
US 7,799,826 · App. 10/418,513 · Granted Sep 21, 2010

Inhibition of fatty acid synthase by beta-lactones and other compounds for inhibition of cellular proliferation

Assignee: Burnham Institute for Medical Research
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,799,826
App. No.
10/418,513
Granted
Sep 21, 2010
Kind
B2
Abstract

The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis.

Claims (18)

1. A method of identifying a beta-lactone that inhibits tumor cell proliferation, comprising:

a) contacting a sample comprising tumor cells with a beta-lactone, wherein the beta-lactone has the formula I:

wherein R 1 , R 2 , R 3 , and R 4 are, independently, hydrogen, an alkyl group, a cycloalkyl group, a heterocyloalkyl group, an alkoxy group, a hydroxyalkyl group, a halogenated alkyl group, an alkoxyalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, an aralkyl group, a hydroxy group, an amine group, an amide, an ester, a carbonate group, a carboxylic acid, an aldehyde, a keto group, an ether group, a halide, a urethane group, a silyl group, or a sulfo-oxo group, and wherein the stereochemistry at carbons a and b is R or S; and

b) measuring the amount of cell proliferation, cell cycle progression, cell cycle arrest, or apoptosis in the sample exposed to the beta-lactone,

whereby a decrease in cell proliferation, a decrease in cell cycle progression, an increase in cell cycle arrest, or an increase in apoptosis in the sample comprising tumor cells exposed to the beta-lactone, relative to the amount of proliferation, cell cycle progression, cell cycle arrest, or apoptosis in a sample comprising tumor cells not contacted with the beta-lactone, identifies a beta-lactone that inhibits proliferation of a tumor cell.

2. The method of claim 1 wherein R 1 is a straight alkyl group.

3. A method of identifying a beta-lactone that inhibits angiogenesis, comprising:

a) contacting a sample comprising endothelial cells with a beta-lactone having the formula I:

wherein R 1 , R 2 , R 3 , and R 4 are, independently, hydrogen, an alkyl group, a cycloalkyl group, a heterocyloalkyl group, an alkoxy group, a hydroxyalkyl group, a halogenated alkyl group, an alkoxyalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, an aralkyl group, a hydroxy group, an amine group, an amide, an ester, a carbonate group, a carboxylic acid, an aldehyde, a keto group, an ether group, a halide, a urethane group, a silyl group, or a sulfo-oxo group, and wherein the stereochemistry at carbons a and b is R or S; and

b) measuring the amount of endothelial cell proliferation, cell cycle progression, or cell cycle arrest in the sample,

whereby a decrease in cell proliferation, a decrease in cell cycle progression, or an increase in cell cycle arrest in the sample, relative to the amount of cell proliferation, cell cycle progression, or cell cycle arrest in a sample comprising endothelial cells not contacted with the beta-lactone, identifies a beta-lactone that inhibits angiogenesis.

4. The method of claim 3 wherein R 1 is a straight alkyl group.

5. A method of identifying a beta-lactone that inhibits angiogenesis, comprising:

a) contacting a sample with a beta-lactone, wherein the sample comprises angiogenic cells and wherein the beta-lactone has the formula I:

wherein R 1 , R 2 , R 3 , and R 4 are, independently, hydrogen, an alkyl group, a cycloalkyl group, a heterocyloalkyl group, an alkoxy group, a hydroxyalkyl group, a halogenated alkyl group, an alkoxyalkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, an aralkyl group, a hydroxy group, an amine group, an amide, an ester, a carbonate group, a carboxylic acid, an aldehyde, a keto group, an ether group, a halide, a urethane group, a silyl group, or a sulfo-oxo group, and wherein the stereochemistry at carbons a and b is R or S, and

b) measuring the amount of angiogenesis in the sample,

whereby a decrease in the amount of angiogenesis in the sample, relative to the amount of angiogenesis in a sample not contacted with the beta-lactone, identifies a beta-lactone that inhibits angiogenesis.

6. The method of claim 5 wherein R 1 is a straight alkyl group.

Assignments (5)
CHANGE OF NAME Recorded Nov 23, 2010
From: THE BURNHAM INSTITUTE
To: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
Reel/Frame 025412/0653 →
CHANGE OF NAME Recorded Nov 23, 2010
From: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
To: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Reel/Frame 025412/0656 →
CONFIRMATORY LICENSE Recorded Jun 4, 2008
From: THE BURNHAM INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021038/0155 →
CONFIRMATORY LICENSE Recorded Aug 4, 2005
From: THE BURNHAM INSTITUTE
To: THE UNITED STATES GOVERNMENT SECRETARY OF THE ARMY ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
Reel/Frame 016836/0416 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2003
From: SMITH, JEFFREY W.; AXELROD, FUMIKO; KRIDEL, STEVEN J.
To: THE BURNHAM INSTIUTE
Reel/Frame 014459/0790 →
Continuity (2)
Provisional Application 6037318100 · Apr 17, 2002
Related Publication 20040024050A1 · Feb 5, 2004